Improvements in self‐confidence and satisfaction with self‐injection after introducing self‐injection of dupilumab in patients with atopic dermatitis

Dupilumab was approved for treating adult patients with atopic dermatitis (AD) refractory to topical therapy in Japan April 2018, and self-injection of dupilumab has been available since May 2019. Subcutaneous medication benefits the healthcare system. However, anxiety about self-injection, lack confidence, complicated procedure could prevent initiating self-injection. In this study, we assessed experience AD treated before after introducing utilizing Self-Injection Assessment Questionnaire (SIAQ). Adult who received by had more than 3 months our hospital from March 1, 2020, June 19, 2021, were included study. Patients rated their perceptions self-injections using SIAQ first Data collected retrospectively charts. on 36 analyzed. The mean age 34.1 ± 11.5 years. Twenty used a prefilled auto-injector, others syringe. Scores self-confidence satisfaction significantly improved Feelings injections over 40 years those felt anxious A strong correlation scores between ease use observed. results not affected clinical severity, gender, or device. Our encourage dither introduce due and/or initiate